Sudden cardiac death and implantable cardioverter-defibrillators

American Family Physician

Volumn 82, Issue 11, 2010, Pages 1357-1366

  Turakhia, Mintu P ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; PLACEBO;

ARTICLE; ARTIFICIAL HEART PACEMAKER; CARDIOVASCULAR RISK; CATHETER ABLATION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATION; DEFIBRILLATOR; ELECTRIC SHOCK; HEART DEATH; HEART EJECTION FRACTION; HEART VENTRICLE FAILURE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HIGH RISK POPULATION; HUMAN; IATROGENIC DISEASE; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PUBLIC HEALTH PROBLEM; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL RATE; THERAPY EFFECT; HEART ARRHYTHMIA; INCIDENCE; REVIEW; UNITED STATES;

ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; INCIDENCE; UNITED STATES;

EID: 79952117293     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(10):e385-e484.
2. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998;98(21):2334-2351.
3. Mehta D, Curwin J, Gomes JA, Fuster V. Sudden death in coronary artery disease: acute ischemia versus myocardial substrate. Circulation. 1997;96(9):3215-3223.
4. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345(20):1473-1482.
5. Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80(6):1675-1680.
6. Pratt CM, Greenway PS, Schoenfeld MH, Hibben ML, Reiffel JA. Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials. Circulation. 1996;93(3):519-524.
7. Nabel EG. Cardiovascular disease [published correction appears in N Engl J Med. 2003;349(6):620]. N Engl J Med. 2003;349(1):60-72.
8. Seidl K, Senges J. Worldwide utilization of implantable cardioverter/defibrillators now and in the future. Card Electrophysiol Rev. 2003;7(1):5-13.
9. Centers for Disease Control and Prevention. State-specific mortality from sudden cardiac death-United States, 1999. MMWR Morb Mortal Wkly Rep. 2002;51(6):123-126.
10. Kannel WB, Thomas HE Jr. Sudden coronary death: the Framingham Study. Ann N Y Acad Sci. 1982;382:3-21.
11. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation. 1992;85(1 suppl):I2-I10.
12. Myerburg RJ, Mitrani R, Interian A Jr, Castellanos A. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation. 1998;97(15):1514-1521.
13. Turakhia MP, Schiller NB, Whooley MA. Prognostic significance of increased left ventricular mass index to mortality and sudden death in patients with stable coronary heart disease (from the Heart and Soul Study). Am J Cardiol. 2008;102(9):1131-1135.
14. Curtis JP, Luebbert JJ, Wang Y, et al. Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA. 2009;301(16):1661-1670.
15. Zipes DP, Roberts D. Results of the international study of the implantable pacemaker cardioverter-defibrillator. A comparison of epicardial and endocardial lead systems. The Pacemaker-Cardioverter-Defibrillator Investigators. Circulation. 1995;92(1):59-65.
16. Myerburg RJ. Implantable cardioverter-defibrillators after myocardial infarction. N Engl J Med. 2008;359(21):2245-2253.
17. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337(22):1576-1583.
18. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101(11):1297-1302.
19. Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102(7):748-754.
20. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons [published correction appears in Circulation. 2009;120(5):e34-e35]. Circulation. 2008;117(21):e350-e408.
21. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335(26):1933-1940.
22. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators [published correction appears in N Engl J Med. 2000;342(17):1300]. N Engl J Med. 1999;341(25):1882-1890.
23. Moss AJ, Zareba W, Hall WJ, et al.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-883.
24. Bardy GH, Lee KL, Mark DB, et al.; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillatorfor congestive heart failure [published correction appears in N Engl J Med. 2005;352(20):2146]. N Engl J Med. 2005;352(3):225-237.
25. Hohnloser SH, Kuck KH, Dorian P, et al.; DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351(24):2481-2488.
26. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292(23):2874-2879.
27. Stevenson LW, Desai AS. Selecting patients for discussion of the ICD as primary prevention for sudden death in heart failure. J Card Fail. 2006;12(6):407-412.
28. Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol. 2003;41(9):1573-1582.
29. Kadish A, Dyer A, Daubert JP, et al.; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151-2158.
30. Department of Health and Human Services. Centers for Medicare and Medicaid Services. CMS manual system. Pub 100-03 Medicare national coverage determinations. January 14, 2008. https://www.cms.gov/transmittals/downloads/R80NCD.pdf. Accessed June 18, 2010.
31. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353(14):1471-1480.
32. Turakhia MP, Varosy PD, Lee K, et al. Impact of renal function on survival in patients with implantable cardioverter-defibrillators. Pacing Clin Electrophysiol. 2007;30(3):377-384.
33. Pellegrini CN, Lee K, Olgin JE, et al. Impact of advanced age on survival in patients with implantable cardioverter defibrillators. Europace. 2008;10(11):1296-1301.
34. Turakhia MP, Wang PJ. "Low ejection fraction prophylaxis" with implantable defibrillators in the elderly: call for a randomized trial? Heart Rhythm. 2009;6(8):1144-1145.
35. Kadish AH, Bello D, Finn JP, et al. Rationale and design for the Defibrillators to Reduce Risk by Magnetic Resonance Imaging Evaluation (DETERMINE) trial. J Cardiovasc Electrophysiol. 2009;20(9):982-987.
36. Lee BK, Olgin JE. Role of wearable and automatic external defibrillators in improving survival in patients at risk for sudden cardiac death. Curr Treat Options Cardiovasc Med. 2009;11(5):360-365.
37. Diamond GA, Kaul S. Bayesian classification of clinical practice guidelines. Arch Intern Med. 2009;169(15):1431-1435.
38. Ezekowitz JA, Rowe BH, Dryden DM, et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med. 2007;147(4):251-262.
39. Agency for Healthcare Research and Quality. Cardiac resynchronization therapy and implantable cardiac defibrillators in left ventricular systolic dysfunction. June 2007. http://www.ahrq.gov/clinic/tp/defibtp.htm. Accessed January 18, 2010.
40. Douglas PS, Khandheria B, Stainback RF, et al. ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Coll Cardiol. 2007;50(2):187-204.
41. Strickberger SA, Benson DW, Biaggioni I, et al. AHA/ACCF Scientific Statement on the evaluation of syncope: from the American Heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke, and the Quality of Care and Outcomes Research Interdisciplinary Working Group; and the American College of Cardiology Foundation: in collaboration with the Heart Rhythm Society: endorsed by the American Autonomic Society [published correction appears in Circulation. 2006;113(14):e697.] Circulation. 2006;113(2):316-327.
42. Gehi AK, Mehta D, Gomes JA. Evaluation and management of patients after implantable cardioverter-defibrillator shock. JAMA. 2006;296(23):2839-2847.
43. Germano JJ, Reynolds M, Essebag V, Josephson ME. Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic? Am J Cardiol. 2006;97(8):1255-1261.
44. Sweeney MO, Wathen MS, Volosin K, et al. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation. 2005;111(22):2898-2905.
45. Alter P, Waldhans S, Plachta E, Moosdorf R, Grimm W. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol. 2005;28(9):926-932.
46. Ellenbogen KA, Wood MA, Swerdlow CD. The Sprint Fidelis lead fracture story: what do we really know and where do we go from here? Heart Rhythm. 2008;5(10):1380-1381.
47. Farwell D, Green MS, Lemery R, Gollob MH, Birnie DH. Accelerating risk of Fidelis lead fracture. Heart Rhythm. 2008;5(10):1375-1379.
48. Maisel WH, Hauser RG, Hammill SC, et al. Recommendations from the Heart Rhythm Society Task Force on Lead Performance Policies and Guidelines: developed in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm. 2009;6(6):869-885.
49. Ladwig KH, Baumert J, Marten-Mittag B, Kolb C, Zrenner B, Schmitt C. Posttraumatic stress symptoms and predicted mortality in patients with implantable cardioverter-defibrillators: results from the prospective living with an implanted cardioverter-defibrillator study. Arch Gen Psychiatry. 2008;65(11):1324-1330.
50. Practice advisory for the perioperative management of patients with cardiac rhythm management devices: pacemakers and implantable cardioverter-defibrillators: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Cardiac Rhythm Management Devices. Anesthesiology. 2005;103(1):186-198.
51. Naehle CP, Strach K, Thomas D, et al. Magnetic resonance imaging at 1.5-T in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol. 2009;54(6):549-555.
52. Stevenson WG, Chaitman BR, Ellenbogen KA, et al.; Subcommittee on Electrocardiography and Arrhythmias of the American Heart Association Council on Clinical Cardiology; Heart Rhythm Society. Clinical assessment and management of patients with implanted cardioverter-defibrillators presenting to nonelectrophysiologists. Circulation. 2004;110(25):3866-3869.